{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:23:28Z","timestamp":1794245008259,"version":"4.9.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert Bosch Center for Tumor Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a 5-year survival of only \u223c13%. Despite incremental advances through combination chemotherapy, most patients relapse rapidly due to profound molecular heterogeneity and intrinsic resistance. Recent genomic and transcriptomic studies have defined distinct PDAC molecular subtypes, classical and basal-like, which differ in differentiation state, prognosis, and therapeutic vulnerability. Classical tumors, marked by GATA6 and hepatocyte nuclear factors, exhibit epithelial identity and relative chemosensitivity, whereas basal-like tumors driven by \u0394Np63 and MYC display mesenchymal and inflammatory programs associated with resistance and poor outcome. Importantly, these subtypes are dynamic, with single-cell and spatial analyses revealing frequent coexistence and therapy-induced transitions, highlighting cellular plasticity as a major determinant of treatment response. Subtype identity is governed by lineage-defining transcription factors, chromatin regulators, and stromal cues that integrate to form reversible epigenetic states. Targeting these mechanisms with inhibitors of EZH2, BET proteins, or CDK9 can restore differentiation programs and resensitize tumors to chemotherapy. Integrating molecular subtyping with epigenetic modulation thus offers a rational path toward biomarker-guided therapy. Continued efforts combining spatially resolved profiling, organoid modeling, and liquid-biopsy monitoring will be essential to capture tumor evolution in real time. Understanding and therapeutically exploiting the transcriptional and epigenetic plasticity in PDAC may ultimately enable reprogramming of resistant states and improve clinical outcomes in this intractable disease.<\/jats:p>","DOI":"10.1093\/gastro\/goag028","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:18:14Z","timestamp":1774239494000},"source":"Crossref","is-referenced-by-count":4,"title":["Epigenetic and transcriptional control of classical and basal-like cell states in pancreatic ductal adenocarcinoma"],"prefix":"10.1093","volume":"14","author":[{"given":"Christina","family":"Parassiadis","sequence":"first","affiliation":[{"name":"Robert Bosch Center for Tumor Diseases , 70376 Stuttgart,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-5805","authenticated-orcid":false,"given":"Steven A","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Robert Bosch Center for Tumor Diseases , 70376 Stuttgart,","place":["Germany"]},{"name":"University of T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026053010365052000_goag028-B1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026053010365052000_goag028-B2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2026053010365052000_goag028-B3","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026053010365052000_goag028-B4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"Suppl 5","key":"2026053010365052000_goag028-B5","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"2026053010365052000_goag028-B6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026053010365052000_goag028-B7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2026053010365052000_goag028-B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"Stein","year":"2016","journal-title":"Br J Cancer"},{"key":"2026053010365052000_goag028-B9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-024-12016-z","article-title":"Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study","volume":"24","author":"Gueiderikh","year":"2024","journal-title":"BMC Cancer"},{"key":"2026053010365052000_goag028-B10","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1007\/s12325-022-02317-9","article-title":"Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world","volume":"39","author":"King","year":"2022","journal-title":"Adv Ther"},{"key":"2026053010365052000_goag028-B11","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026053010365052000_goag028-B12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"2026053010365052000_goag028-B13","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1038\/s41388-022-02448-x","article-title":"The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma","volume":"41","author":"Evan","year":"2022","journal-title":"Oncogene"},{"key":"2026053010365052000_goag028-B14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41467-024-55330-7","article-title":"Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer","volume":"16","author":"Klein","year":"2025","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","article-title":"Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity","volume":"83","author":"Williams","year":"2023","journal-title":"Cancer Res"},{"key":"2026053010365052000_goag028-B16","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.3390\/cancers15235588","article-title":"Alternating gemcitabine\/Nab-Paclitaxel (GA) and 5-FU\/Leucovorin\/Irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): safety and effect","volume":"15","author":"Schroeder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026053010365052000_goag028-B17","doi-asserted-by":"crossref","first-page":"100318","DOI":"10.1016\/j.esmoop.2021.100318","article-title":"Sequential first-line treatment with nab-paclitaxel\/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial","volume":"6","author":"Assenat","year":"2021","journal-title":"ESMO Open"},{"key":"2026053010365052000_goag028-B18","doi-asserted-by":"crossref","first-page":"691185","DOI":"10.3389\/fonc.2021.691185","article-title":"Targeting the stroma in the management of pancreatic cancer","volume":"11","author":"Edwards","year":"2021","journal-title":"Front Oncol"},{"key":"2026053010365052000_goag028-B19","doi-asserted-by":"crossref","first-page":"1002299","DOI":"10.37349\/etat.2025.1002299","article-title":"Pancreatic cancer: failures and hopes\u2014a review of new promising treatment approaches","volume":"6","author":"Cereda","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"2026053010365052000_goag028-B20","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.21037\/jgo-23-85","article-title":"Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review","volume":"14","author":"Tan","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"2026053010365052000_goag028-B21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41698-024-00683-x","article-title":"FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer","volume":"8","author":"Stein","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026053010365052000_goag028-B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"2026053010365052000_goag028-B23","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"2026053010365052000_goag028-B24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"2026053010365052000_goag028-B25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy","volume":"4","author":"B\u00e4rthel","year":"2023","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B26","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41551-024-01273-9","article-title":"Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma","volume":"9","author":"Papargyriou","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"2026053010365052000_goag028-B28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13046-022-02301-9","article-title":"Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses","volume":"41","author":"Shinkawa","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026053010365052000_goag028-B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000519859","article-title":"Epigenetic therapeutic strategies to target molecular and cellular heterogeneity in pancreatic cancer","volume":"38","author":"Versemann","year":"2022","journal-title":"Visc Med"},{"key":"2026053010365052000_goag028-B30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"2026053010365052000_goag028-B32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4884","article-title":"Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4","volume":"242","author":"Hosoda","year":"2017","journal-title":"J Pathol"},{"key":"2026053010365052000_goag028-B33","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","article-title":"SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer","volume":"15","author":"Blackford","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026053010365052000_goag028-B34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","article-title":"Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor \u03b2 signaling","volume":"157","author":"Weissmueller","year":"2014","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"Morton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026053010365052000_goag028-B37","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1038\/s41467-018-07472-8","article-title":"Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis","volume":"9","author":"Santana-Codina","year":"2018","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gim.2014.153","article-title":"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study","volume":"17","author":"Zhen","year":"2015","journal-title":"Genet Med"},{"key":"2026053010365052000_goag028-B40","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2026053010365052000_goag028-B41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jcmgh.2021.09.014","article-title":"KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway","volume":"13","author":"Yi","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026053010365052000_goag028-B42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","article-title":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","volume":"33","author":"Andricovich","year":"2018","journal-title":"Cancer Cell"},{"key":"2026053010365052000_goag028-B43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ncb2916","article-title":"The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma","volume":"16","author":"von Figura","year":"2014","journal-title":"Nat Cell Biol"},{"key":"2026053010365052000_goag028-B44","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/gutjnl-2017-315490","article-title":"SWI\/SNF component ARID1A restrains pancreatic neoplasia formation","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B45","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"key":"2026053010365052000_goag028-B46","first-page":"PO.20.00265","article-title":"Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer","volume":"5","author":"Fusco","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026053010365052000_goag028-B47","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/gutjnl-2015-311256","article-title":"GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer","volume":"66","author":"Martinelli","year":"2017","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B48","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1038\/s41467-019-11812-7","article-title":"Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine","volume":"10","author":"Lomberk","year":"2019","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B49","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.celrep.2018.10.051","article-title":"TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma","volume":"25","author":"Somerville","year":"2018","journal-title":"Cell Rep"},{"key":"2026053010365052000_goag028-B50","doi-asserted-by":"crossref","first-page":"E12343","DOI":"10.1073\/pnas.1812915116","article-title":"DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network","volume":"115","author":"Hamdan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026053010365052000_goag028-B51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","article-title":"Mechanisms of PDAC subtype heterogeneity and therapy response","volume":"8","author":"Espinet","year":"2022","journal-title":"Trends Cancer"},{"key":"2026053010365052000_goag028-B52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","article-title":"Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer","volume":"178","author":"Ligorio","year":"2019","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B53","doi-asserted-by":"crossref","first-page":"102973","DOI":"10.1016\/j.ctrv.2025.102973","article-title":"Medical management of pancreatic cancer: from personalization to broadening treatment strategies","volume":"138","author":"Dusetti","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026053010365052000_goag028-B54","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS Trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026053010365052000_goag028-B55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","article-title":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","volume":"1","author":"Hayashi","year":"2020","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B56","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41467-018-04383-6","article-title":"Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes","volume":"9","author":"Lomberk","year":"2018","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ng.1035","article-title":"GATA6 haploinsufficiency causes pancreatic agenesis in humans","volume":"44","author":"Allen","year":"2011","journal-title":"Nat Genet"},{"key":"2026053010365052000_goag028-B58","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1172\/JCI63352","article-title":"Pancreas-specific deletion of mouse Gata4 and Gata6 causes pancreatic agenesis","volume":"122","author":"Xuan","year":"2012","journal-title":"J Clin Invest"},{"key":"2026053010365052000_goag028-B59","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/gutjnl-2012-303328","article-title":"Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice","volume":"62","author":"Martinelli","year":"2013","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B60","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pgen.1000081","article-title":"Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer","volume":"4","author":"Kwei","year":"2008","journal-title":"PLoS Genet"},{"key":"2026053010365052000_goag028-B61","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O\u2019Kane","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026053010365052000_goag028-B62","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gutjnl-2020-321397","article-title":"A GATA6-centred gene regulatory network involving HNFs and \u0394Np63 controls plasticity and immune escape in pancreatic cancer","volume":"71","author":"Kloesch","year":"2022","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B63","doi-asserted-by":"crossref","first-page":"107625","DOI":"10.1016\/j.celrep.2020.107625","article-title":"HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer","volume":"31","author":"Brunton","year":"2020","journal-title":"Cell Rep"},{"key":"2026053010365052000_goag028-B64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2021-325803","article-title":"GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma","volume":"72","author":"de Andr\u00e9s","year":"2023","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B65","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2024-334374","article-title":"Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer","volume":"74","author":"Ekstrom","year":"2025","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.gastro.2021.04.044","article-title":"TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes","volume":"161","author":"Eyres","year":"2021","journal-title":"Gastroenterology"},{"key":"2026053010365052000_goag028-B67","doi-asserted-by":"crossref","first-page":"e156305","DOI":"10.1172\/JCI156305","article-title":"A p300\/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models","volume":"132","author":"Zhong","year":"2022","journal-title":"J Clin Invest"},{"key":"2026053010365052000_goag028-B68","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.1073\/pnas.1307218110","article-title":"Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026053010365052000_goag028-B69","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/19531","article-title":"p63 is a p53 homologue required for limb and epidermal morphogenesis","volume":"398","author":"Mills","year":"1999","journal-title":"Nature"},{"key":"2026053010365052000_goag028-B70","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/1541-7786.MCR-22-0916","article-title":"Identification of a \u0394Np63-dependent basal-like A subtype-specific transcribed enhancer program (B-STEP) in aggressive pancreatic ductal adenocarcinoma","volume":"21","author":"Wang","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026053010365052000_goag028-B71","doi-asserted-by":"crossref","first-page":"e53381","DOI":"10.7554\/eLife.53381","article-title":"Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation","volume":"9","author":"Somerville","year":"2020","journal-title":"eLife."},{"key":"2026053010365052000_goag028-B72","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41588-024-01790-y","article-title":"Interaction between MED12 and \u0394Np63 activates basal identity in pancreatic ductal adenocarcinoma","volume":"56","author":"Maia-Silva","year":"2024","journal-title":"Nat Genet"},{"key":"2026053010365052000_goag028-B73","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2020-322874","article-title":"Discovery and 3D imaging of a novel \u0394Np63-expressing basal cell type in human pancreatic ducts with implications in disease","volume":"71","author":"Martens","year":"2021","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B74","doi-asserted-by":"crossref","first-page":"11471","DOI":"10.1073\/pnas.1921484117","article-title":"ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer","volume":"117","author":"Somerville","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026053010365052000_goag028-B75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/gutjnl-2021-325811","article-title":"Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells","volume":"72","author":"Alfarano","year":"2023","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B76","doi-asserted-by":"crossref","first-page":"e45313","DOI":"10.7554\/eLife.45313","article-title":"Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer","volume":"8","author":"Adams","year":"2019","journal-title":"Elife"},{"key":"2026053010365052000_goag028-B77","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1158\/0008-5472.CAN-20-0672","article-title":"EZH2 regulates pancreatic cancer subtype identity and tumor progression via transcriptional repression of GATA6","volume":"80","author":"Patil","year":"2020","journal-title":"Cancer Res"},{"key":"2026053010365052000_goag028-B78","doi-asserted-by":"crossref","first-page":"e102808","DOI":"10.15252\/embj.2019102808","article-title":"HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer","volume":"39","author":"Kalisz","year":"2020","journal-title":"EMBO J"},{"key":"2026053010365052000_goag028-B79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.gastro.2023.02.049","article-title":"A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer","volume":"165","author":"Yoo","year":"2023","journal-title":"Gastroenterology"},{"key":"2026053010365052000_goag028-B80","doi-asserted-by":"crossref","first-page":"e154475","DOI":"10.1172\/jci.insight.154475","article-title":"Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer","volume":"7","author":"Krebs","year":"2022","journal-title":"JCI Insight"},{"key":"2026053010365052000_goag028-B81","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s43018-021-00258-w","article-title":"TNF\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer","volume":"2","author":"Tu","year":"2021","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B82","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell Rep"},{"key":"2026053010365052000_goag028-B83","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/gutjnl-2023-329807","article-title":"Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC","volume":"73","author":"Lupo","year":"2024","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"2026053010365052000_goag028-B85","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026053010365052000_goag028-B86","doi-asserted-by":"crossref","first-page":"e2924-e","DOI":"10.1038\/cddis.2017.311","article-title":"Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells","volume":"8","author":"Gao","year":"2017","journal-title":"Cell Death Dis"},{"key":"2026053010365052000_goag028-B87","doi-asserted-by":"crossref","first-page":"18016","DOI":"10.1074\/jbc.RA118.004006","article-title":"MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells","volume":"293","author":"Terashima","year":"2018","journal-title":"J Biol Chem"},{"key":"2026053010365052000_goag028-B88","doi-asserted-by":"crossref","first-page":"717890","DOI":"10.3389\/fmolb.2021.717890","article-title":"Long non-coding RNAs in epithelial-mesenchymal transition of pancreatic cancer","volume":"8","author":"Takahashi","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026053010365052000_goag028-B89","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.tranon.2025.102479","article-title":"Understanding the heterogeneity of pancreatic ductal adenocarcinoma","volume":"60","author":"Iovanna","year":"2025","journal-title":"Transl Oncol"},{"key":"2026053010365052000_goag028-B90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/bs.acr.2023.02.005","article-title":"Tumor heterogeneity: an oncogenic driver of PDAC progression and therapy resistance under stress conditions","volume":"159","author":"P Palma","year":"2023","journal-title":"Adv Cancer Res"},{"key":"2026053010365052000_goag028-B91","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/0008-5472.CAN-22-1190","article-title":"Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers","volume":"82","author":"Mi","year":"2022","journal-title":"Cancer Res"},{"key":"2026053010365052000_goag028-B92","doi-asserted-by":"crossref","first-page":"100726","DOI":"10.1016\/j.modpat.2025.100726","article-title":"Spatial transcriptomics reveals cancer and stromal cell heterogeneity between center and invasive front of pancreatic cancer","volume":"38","author":"Alver","year":"2025","journal-title":"Mod Pathol"},{"key":"2026053010365052000_goag028-B93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-23-1541","article-title":"The evolutionary forest of pancreatic cancer","volume":"15","author":"Mullen","year":"2025","journal-title":"Cancer Discov"},{"key":"2026053010365052000_goag028-B94","doi-asserted-by":"crossref","first-page":"E4410","DOI":"10.1073\/pnas.1501605112","article-title":"Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors","volume":"112","author":"Daemen","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026053010365052000_goag028-B95","doi-asserted-by":"crossref","first-page":"eadj3551","DOI":"10.1126\/sciadv.adj3551","article-title":"Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions","volume":"10","author":"Wolfe","year":"2024","journal-title":"Sci Adv"},{"key":"2026053010365052000_goag028-B96","doi-asserted-by":"crossref","first-page":"e191940","DOI":"10.1172\/JCI191940","article-title":"What\u2019s on the menu? metabolic constraints in the pancreatic tumor microenvironment","volume":"135","author":"Sheehan","year":"2025","journal-title":"J Clin Invest"},{"key":"2026053010365052000_goag028-B97","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2024.05.007","article-title":"Hungry for fat: metabolic crosstalk with lipid-rich CAFs fuels pancreatic cancer","volume":"36","author":"Papavassiliou","year":"2024","journal-title":"Cell Metab"},{"key":"2026053010365052000_goag028-B98","doi-asserted-by":"crossref","first-page":"102089","DOI":"10.1016\/j.molmet.2024.102089","article-title":"Metabolic plasticity in pancreatic cancer: The mitochondrial connection","volume":"92","author":"Ghiglione","year":"2025","journal-title":"Mol Metab"},{"key":"2026053010365052000_goag028-B99","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41419-025-07810-x","article-title":"Therapeutic targeting of FOSL1 and RELA-dependent transcriptional mechanisms to suppress pancreatic cancer metastasis","volume":"16","author":"Aggrey-Fynn","year":"2025","journal-title":"Cell Death Dis"},{"key":"2026053010365052000_goag028-B100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026053010365052000_goag028-B101","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","article-title":"Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer","volume":"26","author":"Shakiba","year":"2025","journal-title":"Nat Immunol"},{"key":"2026053010365052000_goag028-B102","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1038\/s41467-025-61890-z","article-title":"Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B103","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","article-title":"Translational advances in pancreatic ductal adenocarcinoma therapy","volume":"3","author":"Hosein","year":"2022","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B104","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.ebiom.2020.102858","article-title":"Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer","volume":"57","author":"Nicolle","year":"2020","journal-title":"EBioMedicine"},{"key":"2026053010365052000_goag028-B105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","article-title":"Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","volume":"26","author":"Rashid","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026053010365052000_goag028-B106","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","article-title":"Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial","volume":"16","author":"Knox","year":"2025","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41698-022-00299-z","article-title":"Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction","volume":"6","author":"Fraunhoffer","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026053010365052000_goag028-B108","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"2026053010365052000_goag028-B109","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.3390\/ijms252111740","article-title":"Progresses and pitfalls of epigenetics in solid tumors clinical trials","volume":"25","author":"Rossi","year":"2024","journal-title":"IJMS"},{"key":"2026053010365052000_goag028-B110","doi-asserted-by":"crossref","first-page":"1723159","DOI":"10.3389\/freae.2025.1723159","article-title":"Epigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications","volume":"3","author":"Sultana","year":"2025","journal-title":"Front Epigenet Epigenom"},{"key":"2026053010365052000_goag028-B111","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2016-312539","article-title":"Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?","volume":"66","author":"Hessmann","year":"2017","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B112","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2015.216","article-title":"MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies","volume":"35","author":"Hessmann","year":"2016","journal-title":"Oncogene"},{"key":"2026053010365052000_goag028-B113","doi-asserted-by":"crossref","first-page":"e06535","DOI":"10.7554\/eLife.06535","article-title":"Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism","volume":"4","author":"Lu","year":"2015","journal-title":"eLife"},{"key":"2026053010365052000_goag028-B114","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4161\/cbt.12.7.16475","article-title":"Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models","volume":"12","author":"Feldmann","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2026053010365052000_goag028-B115","doi-asserted-by":"crossref","first-page":"104602","DOI":"10.1016\/j.ebiom.2023.104602","article-title":"Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells","volume":"92","author":"Fraunhoffer","year":"2023","journal-title":"EBioMedicine"},{"key":"2026053010365052000_goag028-B116","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gutjnl-2022-328154","article-title":"Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer","volume":"72","author":"Hamdan","year":"2023","journal-title":"Gut"},{"key":"2026053010365052000_goag028-B117","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12885-021-08388-1","article-title":"Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition","volume":"21","author":"Ramaker","year":"2021","journal-title":"BMC Cancer"},{"key":"2026053010365052000_goag028-B118","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1038\/s41467-024-49450-3","article-title":"In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer","volume":"15","author":"Martinez","year":"2024","journal-title":"Nat Commun"},{"key":"2026053010365052000_goag028-B119","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s43018-024-00742-z","article-title":"Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells","volume":"5","author":"Ubhi","year":"2024","journal-title":"Nat Cancer"},{"key":"2026053010365052000_goag028-B120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"2026053010365052000_goag028-B121","doi-asserted-by":"crossref","first-page":"e191939","DOI":"10.1172\/JCI191939","article-title":"KRAS: the Achilles\u2019 heel of pancreas cancer biology","volume":"135","author":"Drizyte-Miller","year":"2025","journal-title":"J Clin Invest"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag028\/67473857\/goag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag028\/67473857\/goag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T14:37:20Z","timestamp":1780151840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag028\/8537317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":121,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag028","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag028"}}